Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지

Posttransplantation Lymphoproliferative Disorder after Liver Transplantation in Pediatric Patients: Report from a Single-center Over 21 Years

간 이식 소아에서 발생한 이식 후 림프 증식 질환: 단일 기관에서의 21년 경험

  • Lee, Jung-Hwa (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Ko, Jae-Sung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Seo, Jeong-Kee (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Yi, Nam-Joon (Department of Surgery, Seoul National University College of Medicine) ;
  • Suh, Kyung-Suk (Department of Surgery, Seoul National University College of Medicine) ;
  • Lee, Kuhn-Uk (Department of Surgery, Seoul National University College of Medicine) ;
  • Kang, Gyeong-Hoon (Department of Pathology, Seoul National University College of Medicine)
  • 이정화 (서울대학교 의과대학 소아과학교실) ;
  • 고재성 (서울대학교 의과대학 소아과학교실) ;
  • 서정기 (서울대학교 의과대학 소아과학교실) ;
  • 이남준 (서울대학교 의과대학 외과학교실) ;
  • 서경석 (서울대학교 의과대학 외과학교실) ;
  • 이건욱 (서울대학교 의과대학 외과학교실) ;
  • 강경훈 (서울대학교 의과대학 병리학교실)
  • Received : 2009.08.17
  • Accepted : 2009.09.22
  • Published : 2009.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To analyze the clinical spectrum of posttransplantation lymphoproliferative disorder (PTLD) after liver transplantation in children. Methods: From January 1988 to June 2009, we retrospectively reviewed the medical records of 8 PTLD cases among 148 pediatric patients underwent liver transplantation. The age at transplantation, time of presentation after transplantation, clinical manifestations, histologic diagnosis, results of EBV (Epstein-Barr virus) assessments, managements and outcomes of PTLD were investigated. Results: The prevalence of PTLD in liver transplant pediatric recipients was 5.4% (8 of 148). The mean age of patients was 25.4${\pm}$21.3 months (range 10 to 67 months). Seven of 8 patients (87.5%) underwent liver transplantation before 1 year of age. The common clinical presentations were persistent fever (8 of 8, 100%) and bloody diarrhea (6 of 8, 75%). PTLD was diagnosed with gastrointestinal endoscopic biopsies in five patients and surgical biopsies in three. Histologic findings showed early lesion in three patients, polymorphic in two, and monomorphic in three. Burkitt lymphoma and lymphoblastic lymphoma were found in two of 3 monomorphic patients. Seven of 8 patients were found with EBV-positive. Eight patients were treated with dose reduction of immunosuppressants and infusion of ganciclovir. Rituximab was added to four patients. PTLD were successfully managed in all patients except one who died of sepsis during chemotherapy. Conclusion: Major risk factor of PTLD was to undergo liver transplantation before 1 year of age. Continuous monitoring for EBV viral load and gastrointestinal endoscopic biopsy may be useful to early detection of PTLD.

목 적: 간 이식 소아에서 발생한 PTLD의 경험을 통해 발현 양상, 발병 위험 인자, 진단 방법, 치료 및 예후에 영향을 줄 수 있는 요인들을 알아보았다. 방 법: 1988년 1월부터 2009년 6월까지 서울대학교 어린이병원에서 간 이식을 받은 소아 148명 중 PTLD로 진단된 8명의 환아들을 대상으로 후향적 분석을 하였다. 이식당시 나이, 이식 후 PTLD 증상이 나타날 때 까지의 기간, 임상적 증상, 조직학적 소견, EBV 검사 결과, 치료 및 경과에 대해 조사하였다. 결 과: 간 이식 후 PTLD의 유병률은 5.4%였고, 발생시기는 조기 PTLD가 6명(75%), 후기 PTLD가 2명(25%)이었다. 대상 환아의 간 이식 당시 나이는 평균8.1${\pm}$4.4개월로, 12개월 미만이 7명(87.5%), 12개월 이후가 1명(12.5%)이었다. PTLD 진단 시 주증상은 발열, 설사, 혈변이었고 모두 장이나 장간막 림프절 침범이 있었다. 3명은 개복 수술로 5명은 상부 위장관 내시경이나 대장 내시경을 통한 조직 검사로 진단되었다. 조직학적 진단은 early lesion이 3명, polymorphic PTLD 2명, monomorphic PTLD 1명, Burkitt 림프종 1명, B 세포 림프종이 1명이었다. EBV는 7명에서 양성을 보였다. 치료는 전례에서 1차 치료로 면역억제제를 중지하고 항바이러스제(ganciclovir)를 투여 하였다. 4명의 환아들에서 rituximab을 추가하였고 Burkitt 림프종과 B 세포림프종으로 진단된 환아들은 각각 항암 치료를 병행하였다. B 세포 림프종으로 진단되어 치료 중에 패혈증으로 1명이 사망하였으며 나머지 7명은 호전되었다. 결 론: 1세 미만에 간 이식을 받은 경우가 PTLD 발생의 주요한 위험 인자였으며, EBV viral load의 지속적인 감시와 위장관 내시경을 통한 조직 검사가 PTLD 조기진단에 유용할 것으로 생각한다.

Keywords

References

  1. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002;236:429-36. https://doi.org/10.1097/00000658-200210000-00005
  2. Lai YC, Ni YH, Jou ST, Ho MC, Wu JF, Chen HL, et al. Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases. Pediatr Transplant 2006;10:390-4. https://doi.org/10.1111/j.1399-3046.2005.00457.x
  3. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004;40:728-35. https://doi.org/10.1016/j.jhep.2004.03.006
  4. 기현균, 손경목, 위유미, 이지영, 문치숙, 오원섭 등. 간이식 후 발생한 림프구 증식성 질환의 임상적 양상. 감염과 화학요법 2006;38:131-9.
  5. 최연호, 이석구, 서정민, 조재원, 김성주, 이광웅 등. 소아 간이식에서 Posttransplant lymphoproliferative disorder(PTLD): 삼성서울병원의 경험. 대한소아소화기영양학회지 2003;6:39-46.
  6. Aucejo F, Rofaiel G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation- J Hepatol 2006;44:19-23. https://doi.org/10.1016/j.jhep.2005.10.008
  7. Duvoux C, Pageaux GP, Vanlemmens C, Roudot- Thoraval F, Vincens-Rolland AL, Hezode C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002;74:1103-9. https://doi.org/10.1097/00007890-200210270-00008
  8. Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003;50:1471-91. https://doi.org/10.1016/S0031-3955(03)00127-5
  9. Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003;75:987-93.
  10. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006;6:1017-24. https://doi.org/10.1111/j.1600-6143.2006.01294.x
  11. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 2007;20:207-18. https://doi.org/10.1111/j.1432-2277.2006.00416.x
  12. Wu JF, Ho MC, Ni YH, Chen HL, Lu CY, Hsu HY, et al. Timing of Epstein-Barr virs acquisition and the course of posttransplantation lymphoproliferative disorder in children. Transplantation 2009;87:758-62. https://doi.org/10.1097/TP.0b013e318198d645
  13. Spada M, Guizzetti M, Petz W, Colledan M, Segalin A, Lucianetti A, et al. Circulating EBV-DNA in the monitoring of EBV infection in pediatric liver transplant recipients. Transplant Proc 2001;33:1835-7. https://doi.org/10.1016/S0041-1345(00)02828-1
  14. Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, et al. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis 2004;6:15-22. https://doi.org/10.1111/j.1399-3062.2004.00044.x
  15. Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatr Transplant 2008:12:778-84. https://doi.org/10.1111/j.1399-3046.2008.00904.x
  16. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-81. https://doi.org/10.1182/blood-2003-12-4287
  17. Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using realtime quantitative polymerase chain reaction. Transplantation 2001;72:1012-9. https://doi.org/10.1097/00007890-200109270-00006
  18. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5:2222-8. https://doi.org/10.1111/j.1600-6143.2005.01002.x
  19. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001;3:79-87. https://doi.org/10.1034/j.1399-3062.2001.003002079.x
  20. Axelrod DA, Holmes R, Thomas SE, Magee JC. Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant 2003;7:223-7. https://doi.org/10.1034/j.1399-3046.2003.00080.x
  21. O'Connor JA, Cogley C, Burton M, Lancaster-Weiss K, Cordle RA. Posttransplantation lymphoproliferative disorder: endoscopic findings. J Pediatr Gastroenterol Nutr 2000;31:458-61. https://doi.org/10.1097/00005176-200010000-00026
  22. Younes BS, Ament ME, McDiarmid SV, Martin MG, Vargas JH. The involvement of the gastrointestinal tract in posttransplant lymphoproliferative disease in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1999;28:380-5. https://doi.org/10.1097/00005176-199904000-00007
  23. Gershman G, Vargas J, Ament ME. The role of endoscopy in diagnosis of lymphoproliferative disorder in the gastrointestinal tract of children after liver transplantation. J Pediatr Gastroenterol Nutr 1998;26:575.
  24. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007;131:1209-18.
  25. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009;24:731-6. https://doi.org/10.1007/s00467-007-0582-3
  26. Frey NV, Tsai DE. The management of posttransplant lymphoproliferative disorder. Med Oncol 2007;24:125-36. https://doi.org/10.1007/BF02698031
  27. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:1604-11. https://doi.org/10.1097/00007890-199812270-00006
  28. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 2001;13:360-7. https://doi.org/10.1097/00001622-200109000-00008
  29. Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder - the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007;13:904-12. https://doi.org/10.1002/lt.21152
  30. Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-7. https://doi.org/10.1182/blood-2005-01-0377
  31. Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006;19:259-69. https://doi.org/10.1111/j.1432-2277.2006.00284.x
  32. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-95. https://doi.org/10.1200/JCO.2005.12.191
  33. Smets F, Sokal EM. Lymphoproliferation in children after liver transplantation. J Pediatr Gastroenterol Nutr 2002;34:499-505. https://doi.org/10.1097/00005176-200205000-00004
  34. Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology 2006;11:355-66. https://doi.org/10.1111/j.1440-1797.2006.00596.x